Vericel Corporation is a public, American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Vericel is a commercial stage company with three marketed drugs. The companys research focus is on cell-based therapies. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2013, Aastrom Bio acquired from Sanofi the "cell therapy and regenerative medicine business" which it had received when purchasing Genzyme in 2011. This transformed the company in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market (which it had not had before).